Targeting the T helper 2 inflammatory axis in atopic dermatitis

International Archives of Allergy and Immunology

Volumn 171, Issue 2, 2016, Pages 71-80

  Moreno, Adriana S ^a   Mcphee, Roderick ^b   Arruda, Luisa Karla ^a   Howell, Michael D ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b MEDIMMUNE   (United States)

Author keywords

Allergy; Atopic dermatitis; Atopic eczema; Hypersensitivity; Immunoglobulin E; Monoclonal antibodies; Pruritus

Indexed keywords

BARICITINIB; CHEMOATTRACT RECEPTOR; CHEMOATTRACTANT; CYTOKINE; DUPILUMAB; FEVIPIPRANT; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; JANUS KINASE; LEBRIKIZUMAB; LIGELIZUMAB; MEPOLIZUMAB; OMALIZUMAB; PITRAKINRA; PLACEBO; STAT PROTEIN; TEZEPELUMAB; THYMIC STROMAL LYMPHOPOIETIN; TOFACITINIB; TRALOKINUMAB; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; MONOCLONAL ANTIBODY; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR;

ATOPIC DERMATITIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EPIDERMIS; GENE TARGETING; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIZATION; SIGNAL TRANSDUCTION; TARGET CELL; TH2 CELL; ANIMAL; DERMATITIS, ATOPIC; DRUG EFFECTS; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; CYTOKINES; DERMATITIS, ATOPIC; HUMANS; IMMUNOGLOBULIN E; JANUS KINASES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TH2 CELLS;

EID: 84995790226     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000451083     Document Type: Review

References (102)

1. Weidinger S, Novak N: Atopic dermatitis. Lancet 2015; 387: 1109-1122
2. Silverberg JI, Silverberg NB: Atopic dermatitis: update on pathogenesis and comorbidities. Curr Dermatol Rep 2012; 1: 168-178
3. Silverberg JI, Hanifin JM: Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population- based study. J Allergy Clin Immunol 2013; 132: 1132-1138
4. Shaw TE, Currie GP, Koudelka CW, Simpson EL: Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol 2011; 131: 67-73
5. Hanifin JM, Reed ML: A population-based survey of eczema prevalence in the United States. Dermatitis 2007; 18: 82-91
6. Bieber T: Atopic dermatitis. N Engl J Med 2008; 358: 1483-1494
7. Bannister MJ, Freeman S: Adult-onset atopic dermatitis. Australas J Dermatol 2000; 41: 225-228
8. Ozkaya E: Adult-onset atopic dermatitis. J Am Acad Dermatol 2005; 52: 579-582
9. Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ: Atopic dermatitis and the atopic march revisited. Allergy 2014; 69: 17-27
10. Tsakok T, Marrs T, Mohsin M, Baron S, Du Toit G, Till S, Carsten F: Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol 2016; 137: 1071-1078
11. Abuabara K, Margolis DJ: Do children really outgrow their eczema, or is there more than one eczema? J Allergy Clin Immunol 2013; 132: 1139-1140
12. Martinez FD: New insights into the natural history of asthma: primary prevention on the horizon. J Allergy Clin Immunol 2011; 128: 939-945.
13. Kattan J: The prevalence and natural history of food allergy. Curr Allergy Asthma Rep 2016; 16: 47
14. Lee E, Lee SH, Kwon J-W, Kim Y, Cho HJ, Yang SI, Jung YH, Kim HY, Seo JH, Kim BJ, Kim HB, Lee SY, Kwon HJ, Hong SJ: Atopic dermatitis phenotype with early onset and high serum IL-13 is linked to the new development of bronchial hyperresponsiveness in school children. Allergy 2016; 71: 692-700
15. Loo EX, Shek LP, Goh A, Teoh OH, Chan YH, Soh SE, Saw SM, Kwek K, Gluckman PD, Godfrey KM, Chong YS, Lee BW, Van Bever HP: Atopic dermatitis in early life: evidence for at least three phenotypes? Results from the GUSTO Study. Int Arch Allergy Immunol 2015; 166: 273-279
16. Van Der Hulst AE, Klip H, Brand PLP: Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol 2007; 120: 565-569
17. von Kobyletzki LB, Bornehag CG, Hasselgren M, Larsson M, Lindstrom CB, Svensson A: Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort. BMC Dermatol 2012; 12: 11
18. Weidinger S, Willis-Owen SAG, Kamatani Y, Baurecht H, Morar N, Liang L, et al: A genome- wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis. Hum Mol Genet 2013; 22: 4841-4856
19. Zheng T, Yu J, Oh MH, Zhu Z: The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res 2011; 3: 67-73
20. Fishbein AB, Vitaterna O, Haugh IM, Bavishi AA, Zee PC, Turek FW, Sheldon SH, Silverberg JI, Paller AS: Nocturnal eczema: review of sleep and circadian rhythms in children with atopic dermatitis and future research directions. J Allergy Clin Immunol 2015; 136: 1170-1177
21. Blome C, Radtke MA, Eissing L, Augustin M: Quality of life in patients with atopic dermatitis: disease burden, measurement, and treatment benefit. Am J Clin Dermatol 2016; 17: 163-169
22. Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NMH, Pirozzi G, Mastey V: Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol 2016; 74: 491-498
23. Mansouri Y, Guttman-Yassky E: Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med 2015; 4: 858-873
24. Howell MD, Parker ML, Mustelin T, Ranade K: Past, present, and future for biologic intervention in atopic dermatitis. Allergy 2015; 70: 887-896
25. Malajian D, Guttman-Yassky E: New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine 2015; 73: 311-318
26. Irvine AD, McLean WHI, Leung DYM: Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011; 365: 1315-1327
27. Thyssen JP, Kezic S: Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 2014; 134: 792-799
28. Linneberg A, Fenger R V, Husemoen LL, Thuesen BH, Skaaby T, Gonzalez-Quintela A, Vidal C, Carlsen BC, Johansen JD, Menne T, Stender S, Melgaard M, Szecsi PB, Berg ND, Thyssen JP: Association between loss-offunction mutations in the filaggrin gene and self-reported food allergy and alcohol sensitivity. Int Arch Allergy Immunol 2013; 161: 234-242
29. Cabanillas B, Novak N: Atopic dermatitis and filaggrin. Curr Opin Immunol 2016; 17: 42: 1-8
30. Otsuka A, Doi H, Egawa G, Maekawa A, Fujita T, Nakamizo S, Nakashima C, Nakajima S, Watanabe T, Miyachi Y, Narumiya S, Kabashima K, et al: Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression. J Allergy Clin Immunol 2014; 133: 139-146
31. Amano W, Nakajima S, Kunugi H, Numata Y, Kitoh A, Egawa G, Dainichi T, Honda T, Otsuka A, Kimoto Y, Yamamoto Y, Tanimoto A, Matsushita M, Miyachi Y, Kabashima K: The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol 2015; 136: 667-677
32. Ming M, Zhao B, Shea CR, Shah P, Qiang L, White SR, Sims DM, He YY: Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge. J Allergy Clin Immunol 2015; 135: 936-945
33. Lio PA, Lee M, LeBovidge J, Timmons KG, Schneider L: Clinical management of atopic dermatitis: practical highlights and updates from the Atopic Dermatitis Practice Parameter 2012. J Allergy Clin Immunol Pract 2014; 2: 361-369
34. Di Filippo P, Scaparrotta A, Rapino D, Cingolani A, Attanasi M, Petrosino MI, Chuang K, Di Pillo S, Chiarelli F: Vitamin D supplementation modulates the immune system and improves atopic dermatitis in children. Int Arch Allergy Immunol 2015; 166: 91-96
35. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, Gieler U, Lipozencic J, Luger T, Oranje AP, Schafer T, Schwennesen T, Seidenari S, Simon D, Stander S, Stingl G, Szalai S, Szepietowski JC, Taieb A, Werfel T, Wollenberg A, Darsow U; European Dermatology Forum; European Academy of Dermatology and Venereology; European Task Force on Atopic Dermatitis; European Federation of Allergy; European Society of Pediatric Dermatology; Global Allergy and Asthma European Network: Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26: 1045-1060
36. Chi CC, Kirtschig G, Aberer W, Gabbud JP, Lipozenčić J, Karpati S, Haustein UF, Zuberbier T, Wojnarowska F: Evidence-based (S3) guideline on topical corticosteroids in pregnancy. Br J Dermatol 2011; 165: 943-952
37. Boguniewicz M: Atopic dermatitis: the updated practice parameter and beyond. Allergy Asthma Proc 2014; 35: 429-434
38. Proudfoot LE, Powell AM, Ayis S, Barbarot S, Baselga Torres E, Deleuran M, Folster-Holst R, Gelmetti C, Hernandez-Martin A, Middelkamp- Hup MA, Oranje AP, Logan K, Perkin M, Patrizi A, Rovatti G, Schofield O, Spuls P, Svensson A, Vestergaard C, Wahlgren CF, Schmitt J, Flohr C; European Dermato-Epidemiology Network (EDEN): The European Treatment of Severe Atopic Eczema in Children Taskforce (TREAT) survey. Br J Dermatol 2013; 169: 901-909
39. Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA: New insights into atopic dermatitis. J Clin Invest 2004; 113: 651-657
40. Gittler JK, Shemer A, Suarez-Farinas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQ, Mitsui H, Cardinale I, De Guzman Strong C, Krueger JG, Guttman-Yassky E: Progressive activation of T(h)2/T(h)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012; 130: 1344-1354
41. Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, Darst MA, Gao B, Boguniewicz M, Travers JB, Leung DY: Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003; 171: 3262-3269
42. Jeong CW, Ahn KS, Rho NK, Park YD, Lee DY, Lee JH, Lee ES, Yang JM: Differential in vivo cytokine mRNA expression in lesional skin of intrinsic versus extrinsic atopic dermatitis patients using semiquantitative RTPCR. Clin Exp Allergy 2003; 33: 1717-1724
43. Teraki Y, Sakurai A, Izaki S: IL-13/IL-22-coproducing T cells, a novel subset, are increased in atopic dermatitis. J Allergy Clin Immunol 2013; 132: 971-974
44. Czarnowicki T, Gonzalez J, Shemer A, Malajian D, Xu H, Zheng X, Khattri S, Gilleaudeau P, Sullivan-Whalen M, Suarez-Farinas M, Krueger JG, Guttman-Yassky E: Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol 2015; 136: 104-115
45. Chan LS, Robinson N, Xu L: Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 2001; 117: 977-983
46. Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z: Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol 2008; 129: 742-751
47. Lee GR, Flavell RA: Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma. Int Immunol 2004; 16: 1155-1160
48. Sehra S, Yao Y, Howell MD, Nguyen ET, Kansas GS, Leung DY, Travers JB, Kaplan MH: IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol 2010; 184: 3186-3190
49. Howell MD, Kim BE, Gao P, Grant A V, Boguniewicz M, Debenedetto A, Schneider L, Beck LA, Barnes KC, Leung DY: Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007; 120: 150-155
50. Kim BE, Leung DYM, Boguniewicz M, Howell MD: Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 2008; 126: 332-337
51. Howell MD, Fairchild HR, Kim BE, Bin L, Boguniewicz M, Redzic JS, Hansen KC, Leung DY: Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol 2008; 128: 2248-2258
52. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, Berger AE, Zhang K, Vidyasagar S, Yoshida T, Boguniewicz M, Hata T, Schneider LC, Hanifin JM, Gallo RL, Novak N, Weidinger S, Beaty TH, Leung DY, Barnes KC, Beck LA: Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 2011; 127: 773-786
53. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-1160
54. Albanesi C, Fairchild HR, Madonna S, Scarponi C, De Pita O, Leung DY, Howell MD: IL-4 and IL-13 negatively regulate TNF-Alpha- And IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol 2007; 179: 984-992
55. Howell MD, Wollenberg A, Gallo RL, Flaig M, Streib JE, Wong C, Pavicic T, Boguniewicz M, Leung DY: Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006; 117: 836-841
56. Brauweiler AM, Goleva E, Leung DY: Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). J Invest Dermatol 2014; 134: 2114-2121
57. Burmeister Getz E, Fisher DM, Fuller R: Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J Clin Pharmacol 2009; 49: 1025-1036
58. Antoniu SA: Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. Curr Opin Investig Drugs 2010; 11: 1286-1294
59. Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suarez- Farinas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR: Dupilumab treatment in adults with moderate-To-severe atopic dermatitis. N Engl J Med 2014; 371: 130-139
60. Thaci D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M: Efficacy and safety of dupilumab in adults with moderateto- severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2015; 387: 40-52
61. Simon D, Braathen LR, Simon HU: Eosinophils and atopic dermatitis. Allergy 2004; 59: 561-570
62. Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP: Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 2012; 42: 712-737
63. Liu FT, Goodarzi H, Chen HY: IgE, mast cells, and eosinophils in atopic dermatitis. Clin Rev Allergy Immunol 2011; 41: 298-310
64. Spergel JM, Mizoguchi E, Oettgen H, Bhan AK, Geha RS: Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. J Clin Invest 1999; 103: 1103-1111
65. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, Hijnen DJ, Plotz S, Knol EF, Kapp A, Bruijnzeel-Koomen CA, Ring J, De Bruin-Weller MS: Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005; 60: 693-696
66. Oldhoff JM, Darsow U, Werfel T, Bihari IC, Katzer K, Laifaoui J, Plotz S, Kapp A, Knol EF, Bruijnzeel-Koomen CA, Ring J, De Bruin- Weller MS: No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol 2006; 141: 290-294
67. Comeau MR, Ziegler SF: The influence of TSLP on the allergic response. Mucosal Immunol 2010; 3: 138-147
68. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, Lauerma A, Smith K, Gorman D, Zurawski S, Abrams J, Menon S, McClanahan T, De Waal-Malefyt Rd R, Bazan F, Kastelein RA, Liu YJ: Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3: 673-680
69. Wang Y, Liu Y: Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses. Clin Exp Allergy 2009; 39: 798-806
70. Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A, Comeau MR, Campbell DJ, Ziegler SF: Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 2005; 202: 541-549
71. He R, Oyoshi MK, Garibyan L, Kumar L, Ziegler SF, Geha RS: TSLP acts on infiltrating effector T cells to drive allergic skin inflammation. Proc Natl Acad Sci USA 2008; 105: 11875-11880
72. Jessup HK, Brewer AW, Omori M, Rickel EA, Budelsky AL, Yoon BR, Ziegler SF, Comeau MR: Intradermal administration of thymic stromal lymphopoietin induces a T cell and eosinophil-dependent systemic Th2 inflammatory response. J Immunol 2008; 181: 4311-4319
73. Wilson SR, The L, Batia LM, Beattie K, Katibah GE, McClain SP, Pellegrino M, Estandian DM, Bautista DM: The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 2013; 155: 285-295
74. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD: Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2015; 15: 35-50
75. Rochman Y, Kashyap M, Robinson GW, Sakamoto K, Gomez-Rodriguez J, Wagner KU, Leonard WJ: Thymic stromal lymphopoietin- mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signalling. Proc Natl Acad Sci USA 2010; 107: 19455-19460
76. Levy LL, Urban J, King BA: Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 2015; 73: 395-399
77. Kostenis E, Ulven T: Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med 2006; 12: 148-158
78. Spik I, Brenuchon C, Angeli V, Staumont D, Fleury S, Capron M, Trottein F, Dombrowicz D: Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J Immunol 2005; 174: 3703-3708
79. Chevalier E, Stock J, Fisher T, Dupont M, Fric M, Fargeau H, Leport M, Soler S, Fabien S, Pruniaux MP, Fink M, Bertrand CP, McNeish J, Li B: Cutting edge: chemoattractant receptor- homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment. J Immunol 2005; 175: 2056-2060
80. Satoh T, Moroi R, Aritake K, Urade Y, Kanai Y, Sumi K, Yokozeki H, Hirai H, Nagata K, Hara T, Utsuyama M, Hirokawa K, Sugamura K, Nishioka K, Nakamura M: Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol 2006; 177: 2621-2629
81. Oiwa M, Satoh T, Watanabe M, Niwa H, Hirai H, Nakamura M, Yokozeki H: CRTH2-dependent, STAT6-independent induction of cedar pollen dermatitis. Clin Exp Allergy 2008; 38: 1357-1366
82. Boehme SA, Chen EP, Franz-Bacon K, Sasik R, Sprague LJ, Ly TW, Hardiman G, Bacon KB: Antagonism of CRTH2 ameliorates chronic epicutaneous sensitization-induced inflammation by multiple mechanisms. Int Immunol 2009; 21: 1-17
83. Boehme SA, Franz-Bacon K, Chen EP, Sasik R, Sprague LJ, Ly TW, Hardiman G, Bacon KB: A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation. Int Immunol 2009: 21: 81-93
84. Hijnen D, Nijhuis E, Bruin-Weller M, Holstege F, Koerkamp MG, Kok I, Bruijnzeel- Koomen C, Knol E: Differential expression of genes involved in skin homing, proliferation, and apoptosis in CD4+ T cells of patients with atopic dermatitis. J Invest Dermatol 2005; 125: 1149-1155
85. Iwasaki M, Nagata K, Takano S, Takahashi K, Ishii N, Ikezawa Z: Association of a new-Type prostaglandin D2 receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis. J Invest Dermatol 2002; 119: 609-616
86. Novak N, Bieber T: Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003; 112: 252-262
87. Oettgen HC, Geha RS: IgE in asthma and atopy: cellular and molecular connections. J Clin Invest 1999; 104: 829-835
88. Poulsen LK, Hummelshoj L: Triggers of IgE class switching and allergy development. Ann Med 2007; 39: 440-456
89. Denby KS, Beck LA: Update on systemic therapies for atopic dermatitis. Curr Opin Allergy Clin Immunol 2012; 12: 421-426
90. Krathen RA, Hsu S: Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005; 53: 338-340
91. Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, Nadeau KC: Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 2013; 162: 89-93
92. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB: Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008; 29: 530-537
93. Park SY, Choi MR, Na JI, Youn SW, Park KC, Huh CH: Recalcitrant atopic dermatitis treated with omalizumab. Ann Dermatol 2010; 22: 349-352
94. Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S, Andres C, Schnopp C, Ring J, Hein R, Ollert M, Mempel M: Lowdose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007; 120: 1223-1225
95. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G: Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - A randomized, placebocontrolled and double blind pilot study. J Dtsch Dermatol Ges 2010; 8: 990-998
96. Hotze M, Baurecht H, Rodriguez E, Chapman- Rothe N, Ollert M, Folster-Holst R, Adamski J, Illig T, Ring J, Weidinger S: Increased efficacy of omalizumab in atopic dermatitis patients with wild-Type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 2014; 69: 132-135
97. Arm JP, Bottoli I, Skerjanec A, Floch D, Groenewegen A, Maahs S, Owen CE, Jones I, Lowe PJ: Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-Affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 2014; 44: 1371-1385
98. Novartis Clinical Trial No. CQGE031X2201. http://www.novctrd.com (accessed March 15, 2016)
99. Ando T, Hashiro M, Noda K, Adachi J, Hosoya R, Kamide R, Ishikawa T, Komaki G: Development and validation of the psychosomatic scale for atopic dermatitis in adults. J Dermatol 2006; 33: 439-450
100. Kiebert G, Sorensen S V., Revicki D, Fagan SC, Doyle JJ, Cohen J, Fivenson D: Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 2002; 41: 151-158
101. Sheldon E, Schwickart M, Li J, Kim K, Crouch S, Parveen S, Kell C, Birrell C: Pharmacokinetics, pharmacodynamics, and safety of MEDI4212, an anti-IgE monoclonal antibody, in subjects with atopy: a phase I study. Adv Ther 2016; 33: 225-251
102. Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, Wu R, Ardeleanu M, Graham NM, Pirozzi G, Sutherland ER, Mastey V: Dupilumab therapy provides clinically meaningful improvement in patientreported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol 2016; 75: 506-515